Showing results (181-190 of 682) with videos related to

Sort By:
Pageof 69
Core Evidence|January 23, 2015
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapyJennifer Dinnel, Bonny L Moore, Brent M Skiver, et al.
Leukemia & Lymphoma|January 12, 2019
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosisPrithviraj Bose, Mahesh Swaminathan, Naveen Pemmaraju, et al.
International Journal of Hematology|September 4, 2009
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformationMatjaz Sever, Hagop Kantarjian, Sherry Pierce, et al.
International Journal of Hematology|November 11, 2016
Primary autoimmune myelofibrosis: a case report and review of the literatureYasmin Abaza, C Cameron Yin, Carlos E Bueso-Ramos, et al.
Cancer|September 2, 2006
Novel approaches in the treatment of systemic mastocytosisAlfonso Quintas-Cardama, Ahmed Aribi, Jorge Cortes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2018
Breakthrough Fungal Infections in Patients With Leukemia Receiving IsavuconazoleCaitlin R Rausch, Adam J DiPippo, Prithviraj Bose, et al.
Leukemia & Lymphoma|December 30, 2009
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosisSameer A Parikh, Hagop M Kantarjian, Mary Ann Richie, et al.
Anti-Cancer Agents in Medicinal Chemistry|December 17, 2008
Chemical and clinical development of darinaparsin, a novel organic arsenic derivativeAlfonso Quintás-Cardama, Srdan Verstovsek, Emil Freireich, et al.
Haematologica|August 1, 2020
Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosisIvo Veletic, Sanja Prijic, Taghi Manshouri, et al.
Annals of Hematology|October 9, 2021
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approvalSrdan Verstovsek, Shreekant Parasuraman, Jingbo Yu, et al.
Pageof 69